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Applying serologic procedures to the detection of RBC and lym-
phocyte antigens has facilitated the identification of granulo-
cyte antigens with established clinical significance, which are 
now classified in the human neutrophil antigen system. Granu-
locyte alloantibodies and autoantibodies have been implicated 
in a variety of clinical conditions including alloimmune neutro-
penia, autoimmune neutropenia, febrile and severe pulmonary 
transfusion reactions, drug-induced neutropenia, refractori-
ness to granulocyte transfusions, and immune neutropenia 
after hematopoietic stem cell transplantation. Although the 
intrinsically fragile nature of granulocytes contributes to the in-
herent challenges of granulocyte serology, several advances in 
laboratory procedures have improved detection of granulocyte 
antibodies. This review will provide a current perspective about 
the importance and use of granulocyte serology for detection 
of granulocyte antibodies that have significant medical effects. 
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It has now been half a century since Lalezari1 described the first case of neonatal neutropenia attributable to transplacental transfer of granulocyte-specific antibod-
ies, thus initiating the field of granulocyte serology. This 
event fostered several decades of work directed at the iden-
tification of granulocyte-specific antigens (and antibodies), 
methods for their detection, and an appreciation for their 
clinical significance. In many ways, granulocyte serology 
developed along the laboratory footprints of RBC and hu-
man lymphocyte antigen (HLA) serology with one major 
exception—granulocytes could not be preserved for testing 
purposes. The requirement for fresh cells was and contin-
ues to be a major impediment for wide-scale implementa-
tion of granulocyte immunobiology studies. Although the 
number of laboratories worldwide that specialize in this 
technology is limited, the clinical significance of granulo-
cyte antibodies has not diminished and is now supporting 
the development of new methodologies that have the poten-
tial to enhance the utility of testing and growth of this field. 
Therefore, as we move ahead, it is important to (1) focus 
on the clinical events that support the need for granulocyte 
serology, (2) understand the benefits and limitations of the 
current serologic assays, and (3) evaluate the application of 
new technologies for the detection of granulocyte antigens 
and antibodies.
Clinical Significance   
Alloimmune Neonatal Neutropenia 
 Neutropenia observed in the neonate is primarily the 
result of neutrophil-specific alloantibodies transplacentally 
transferred to the fetus from the maternal circulation. The 
presence of these human neutrophil antigen (HNA) anti-
bodies most likely is the result of prenatal maternal sensi-
tization by fetal neutrophils crossing the placental barrier, 
although the antibodies may have also arisen in association 
with autoimmune diseases such as systemic lupus 
erythematosus or rheumatoid arthritis.2,3 Mater-
nal alloimmunization can occur anytime after the first 
trimester of pregnancy. Once present in the fetal circula-
tion, maternal HNA antibodies will bind to the mature fetal 
cells expressing the corresponding neutrophil alloantigens, 
as the neutrophil precursor cells are spared.4 Neonates af-
fected by alloimmune neonatal neutropenia (ANN) are al-
most always neutropenic at birth, although cases have been 
reported in which the neutropenia has been delayed by 1 to 
3 days.4 ANN is often asymptomatic and goes undiscovered 
unless the deficit of the neutrophils is profound enough 
(absolute neutrophil count < 1.5 × 109/L) that the newborn 
becomes susceptible and succumbs to infection caused by 
bacterial or fungal pathogens. These children commonly 
present with fever, malaise, lethargy, skin infections such 
as cellulitis and omphalitis, mucosal and respiratory infec-
tions (stomatitis, otitis media, and pneumonia), urinary 
infections, and very rarely septicemia. These infections are 
usually mild, but fatalities have been reported in 5 percent 
of cases.5 As there are numerous reasons for neonatal neu-
tropenia (i.e., congenital, antibody-mediated destruction, 
or infection that decreases hemopoietic cell production), 
detection of these maternal neutrophil antibodies is very 
important for determining the mechanism causing neutro-
penia. This allows the physician to focus on the appropriate 
treatment. The presence of maternal antibodies can persist 
up to 6 months after birth although antibodies and clini-
cal effects usually dissipate more quickly. The incidence of 
ANN has been estimated to be 0.1 to 0.2 percent.6,7 Cur-
rently, neutrophil antibodies with the following specificities 
have been implicated in cases of ANN: HNA-1a,8–10 HNA-
1b,11 HNA-1c,12 FcγRIIIb (CD16),13,14 HNA-2a,15 HNA-3a,16 
and HNA-4a.17
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Autoimmune Neutropenia  
 Autoimmune neutropenia (AIN) occurs in both in-
fants and adults. It is the most common form of chronic 
neutropenia in infants. Severe neutropenia is usually recog-
nized 4 to 7 months after birth.4 In the vast majority of AIN 
cases infants exhibit relatively mild clinical issues such as 
stomatitis, otitis, and respiratory infections. The presence 
of clinical symptoms lessens as the child becomes older. 
Neutropenia in infants is self-limited with complete reso-
lution commonly observed within 7 to 24 months.18 How-
ever, this condition necessitates aggressive hygienic care of 
infants to prevent infection and vigorous therapy that may 
include severe antibiotic therapy along with treatment with 
recombinant G-CSF and IVIG when infection occurs. Cell 
destruction can occur in the peripheral circulation in addi-
tion to interference with myelopoiesis in the bone marrow. 
Complete blood counts demonstrate absolute neutropenia, 
although random fluctuations in the neutrophil count can 
range from zero to near normal.
 AIN is also observed in adults. Monocytosis with or 
without lymphopenia may also be present.19 As in infants, 
the bone marrow commonly demonstrates an absence of 
mature cells with an increase in myeloid precursors. This 
apparent imbalance of precursors to mature segmented 
neutrophils is distinct in cause from the maturation arrest 
that occurs in congenital defects of neutrophils or hemato-
logic malignancy. Unlike RBC autoantibodies, antibodies in 
AIN are often reported to have specificity that can include 
HNA-1a, HNA-1b, and HNA-2a.18–20
Drug-Induced Neutropenia   
 Although neutrophil antibodies are believed to be in-
volved in drug-induced neutropenia, neither the precise 
mechanisms nor the particular antigens on the cell surface 
have yet been clarified. Some cases of drug-induced granu-
locytopenias probably result from direct marrow toxicity, 
although immune-mediated processes also occur. Quinine, 
quinidine, ibuprofen, and psychotropic medications such 
as clozapine are recognized as potential causes of neutrope-
nia.21–23 Drug-dependent antibodies have been found to re-
act with both granulocytes and granulocyte precursors. The 
FcγRIIIb and CD177 neutrophil glycoproteins have been 
reported to form neoantigens with drugs or their metabo-
lites, which are recognized by drug-dependent neutrophil 
antibodies.
Transfusion Reactions   
 Antibodies to neutrophil and HLA antigens can result 
in a variety of transfusion reactions. The spectrum of sever-
ity can range from mild febrile reactions to death in the case 
of severe transfusion-related acute lung injury (TRALI). Re-
cently TRALI has been shown to be the most common cause 
of transfusion-related fatalities in the United States.24
 Febrile nonhemolytic transfusion reactions are com-
mon and can occur when blood products containing WBCs 
are transfused into patients who have leukocyte antibodies.25 
The occurrence of febrile reactions has been mitigated with 
the use of leukocyte-reduced RBCs and platelet products.
 As early as 1951 blood transfusions were implicated in 
noncardiogenic lung edema.26 The term TRALI was con-
ceived in 1985 when Popovsky and Moore27 investigated a 
series of 36 patients with well-defined transfusion-related 
acute lung injury. They detected leukocyte (HLA and HNA) 
antibodies in 89 percent of the implicated donors. Seventy-
two percent of these patients were treated with mechanical 
ventilation, and 6 percent died. The leading theories for the 
cause of TRALI involve the priming or activation of neu-
trophils with antigen-antibody interactions, inducing an 
acute inflammatory response.28 Antibodies to HLA class I 
and class II as well as HNAs have all been implicated in the 
development of TRALI.28
 Even though HLA class I alloantibodies are the most 
frequently encountered WBC antibodies in implicated blood 
donors, they may act as much weaker triggers of acute lung 
injury when compared with HLA class II and HNA antibod-
ies. In a study designed to investigate leukocyte antibody 
specificities in severe TRALI reactions, Reil et al.29 reported 
that even though 73 percent of leukocyte antibodies identi-
fied in their donor population were HLA class I, HLA class 
II and HNA antibodies were associated with 81 percent of 
the antibody-mediated TRALI cases.29 Specifically, in their 
36 reported cases, 17 were elicited by blood products con-
taining HLA class II antibodies, and HNA antibodies were 
implicated in 10 cases. Of the 10 fatal outcomes, 6 were 
linked to HNA-3a antibodies in the transfused blood prod-
ucts, and HLA class II antibodies were associated with 3 fa-
talities.
 Although leukocyte agglutinating (aggregating) anti-
bodies have been frequently associated with TRALI,30–34 
the ability of HNA-3a antibodies to also prime and activate 
neutrophils in the pulmonary vasculature is thought to be 
central to severe and fatal TRALI.35 Studies have now shown 
that in addition to HNA-3a antibodies, HNA-2a and HNA-
4a antibodies also have the ability to prime neutrophils in 
vitro.36–38
 Although the pathophysiology of TRALI appears com-
plex and remains under investigation,39 substantial clinical 
and scientific information suggests that HLA (especially 
class II) and HNA antibodies do play a significant role in 
this disorder.28 Efforts are now being focused on detecting 
HLA and HNA antibodies in donors both to retrospectively 
investigate the cause of acute lung injury in blood recipients 
and to serve as a valuable strategy in preventing TRALI by 
identifying donors who may be responsible for the transfu-
sion reaction.
Granulocyte Antigens   
 Granulocyte-specific antigens are those with a tissue 
distribution restricted to granulocytes (neutrophils, eosino-
phils, and basophils), whereas neutrophil-specific antigens 
are only present on neutrophils. Because of the difficulty in 
characterizing antigens on basophils and eosinophils, many 
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antigens described as neutrophil-specific have not been 
tested to determine whether they are present only on neu-
trophils or on all granulocytes. Although granulocyte (neu-
trophil) antigen systems were initially identified through 
studies of ANN and AIN, both terms, granulocyte and neu-
trophil, have been used to describe the alloantigens.
Nomenclature   
 Lalezari and colleagues8 identified the first granulo-
cyte antigen during their investigation of a neonate with 
transient ANN and subsequently proposed the first no-
menclature system for these antigens. Because their stud-
ies indicated that the antigen was neutrophil-specific, they 
designated it the N system and the antigens were named in 
chronologic order of discovery. The antigens were labeled 
alphabetically and the alleles were described numerically. 
The system eventually classified seven antigens: NA1,8 
NA2,40 NB1,41 NB2,42,43 NC1,44 ND1,45 and NE1,46 which be-
came the foundation for granulocyte serology.
 During this same period and subsequently, several dif-
ferent granulocyte antigens were identified. Some were 
specific for granulocytes (or neutrophils): HGA-3, GA, 
GB, GC, Gr1, Gr247–49; some were shared with other cells 
or tissues: HGA-1, 5a, 5b, 9, MART47,50–52; and some had 
unclassified distribution: CN1, KEN, LAN, LEA, SL.53–56 
All of these granulocyte antigens were detected with sera 
from patients with autoantibodies or alloantibodies di-
rected against granulocytes, using traditional blood group 
serologic techniques such as agglutination, immunofluo-
rescence, and cytotoxicity. Unfortunately, most of these 
antigens have not been further classified owing to the lack 
of sufficient biologic material for study.
 Although this led to a consolidation of 
individuals working in this field, advances 
were made and efforts were directed at im-
munobiochemical, genetic, and structural 
or functional studies for a few of the well-
classified granulocyte antigens. With the 
advent of this information came the need 
for a standardized granulocyte antigen no-
menclature system based on the molecules 
carrying the antigens and the genes encod-
ing each allele. In 1999, the Granulocyte 
Antigen Working Party of the International 
Society of Blood Transfusion (ISBT) estab-
lished a new nomenclature system for the 
well-characterized granulocyte antigens, 
which was based on the glycoprotein loca-
tion of the antigens.57 In this system the 
granulocyte antigens are called human neu-
trophil alloantigens to indicate they are ex-
pressed on neutrophils; however, this does 
not imply that they are neutrophil-specific. 
Each antigen group is assigned a number, 
and polymorphisms within the group are 
designated alphabetically in sequential order 
of detection. The HNA system currently includes seven an-
tigens, which are restricted to five antigen groups. The key 
features of the HNA system are summarized in Table 1. An 
extensive amount of information is now known about these 
antigens, and the reader is referred to Bux’s recent and 
comprehensive review about the antigens that constitute 
this system.58
 HNA-1 is the best-characterized group, and it contains 
three antigens: HNA-1a, HNA-1b, and HNA-1c. The HNA-1 
antigens are expressed only on neutrophils, and antibodies 
to these antigens are frequently implicated in cases of al-
loimmune or autoimmune neutropenia.18,58 The antigens are 
epitopes that occur on the neutrophil low-affinity FcγRIIIb 
receptor (CD16). This molecule binds the Fc region of IgG 
antibodies complexed to other antigens or immunoglobu-
lins. The gene frequencies of HNA-1a, HNA-1b, and HNA-
1c vary among different ethnic populations.58 Furthermore, 
individuals lacking FcγRIIIb have been identified. These in-
dividuals do not express the HNA-1 antigens on their neu-
trophils, thus presenting as an HNA-1 null phenotype.54,62
 The HNA-2 group has one characterized antigen—
HNA-2a—which is located on a 58- to 64-kDa glycoprotein 
that is expressed only on neutrophils.63 Although HNA-2a is 
a high-frequency antigen phenotype (i.e., greater than 90% 
for most populations), it is unique in that it is expressed 
on subpopulations of neutrophils among antigen-positive 
people. The expression of HNA-2a is greater on neutrophils 
from women than men, and two or three subpopulations 
of expression are often detected: one population that lacks 
HNA-2a expression and one or two populations that express 
the antigen but with different intensities.64 The functional 
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AIN = autoimmune neutropenia; ANN = alloimmune neonatal neutropenia; CD = 
clusters of differentiation; CR3 = complement receptor 3; CTL2 = choline trans-
porter-like protein 2; FcγRIIIb = Fc gamma receptor IIIb; HNA = human neutrophil 
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role of HNA-2a is not known, and antibodies to this antigen 
have been associated with AIN,20 ANN,65 febrile transfusion 
reactions,66 TRALI,67 and drug-dependent neutropenia.68
 HNA-3a is expressed on granulocytes, lymphocytes, 
platelets, endothelial cells, kidney, spleen, and placental 
cells.50 It is a high-frequency antigen located on choline 
transporter-like protein 2 (CTL2), and its function is not 
known.59,60 Alloantibodies to HNA-3a have been associated 
with occasional cases of febrile transfusion reactions69 and 
one case of ANN.70 Although antibodies to HNA-3a are rare, 
their major clinical significance has been their association 
with serious and fatal TRALI events.32–34
 The HNA-4 and HNA-5 antigens are located on subunits 
of the β2 integrin family (CD11a and CD11b molecules). In-
tegrins are a large family of adhesive receptors that are es-
sential for cell-cell interactions and cell trafficking. HNA-4a 
is an epitope on the α M (CD11b) chain of CD11b/CD18 (the 
CR3 molecule), and HNA-5a is an epitope on the α L chain 
(CD11a) of CD11a/CD18 (the leukocyte function antigen-1 
[LFA-1] molecule).71 HNA-4a is expressed on granulocytes, 
monocytes, and natural killer cells, whereas HNA-5a is ex-
pressed on all leukocytes.58 Alloantibodies to HNA-4a can 
cause ANN,72 and the CD11b/CD18 complex has been re-
ported to be the target of autoantibodies.18,73 To date, HNA-
5a antibodies have not been clinically associated with 
neutropenia.
 A general consensus exists that granulocytes do not ex-
press ABO antigens74 or HLA class II antigens.75 Although 
the density of HLA class I antigens on granulocytes is fairly 
low, it can vary among individuals.76 Therefore, these anti-
gens must be taken into consideration when patient samples 
are tested for granulocyte antibodies. HLA class I antigens 
may be of particular interest during granulocyte transfusion 
for neutropenic patients as these antigens, in granulocyte 
concentrates, may be introduced in high amounts to recipi-
ents with preformed class I antibodies. Transfusion reac-
tions including TRALI have been observed in this situation, 
and the antigen-antibody interaction has been proposed to 
limit effectiveness of the transfusion.77–79
Serologic Testing  
 The detection of HNA antibodies is labor intensive and 
technically challenging. Unlike HLA testing, commercial 
test kits are not readily available for the detection of granu-
locyte antibodies by solid-phase methodologies. Therefore, 
intact viable granulocytes are required for granulocyte an-
tibody screening. Granulocytes are intrinsically designed 
to respond to physiologic priming signals, so they must be 
handled very carefully to prevent activation. Once activated 
it is impossible to interpret any serologic test results involv-
ing these cells, as false-positive test results abound. Granu-
locytes are also extremely labile and must be used within 
24 hours of collection, necessitating ready access to panel 
cell donors with the needed antigen phenotypes. Although 
many have tried, attempts to develop short-term or long-
term granulocyte preservation procedures have been un-
successful, thus requiring that fresh suspensions of granu-
locytes be prepared daily for testing procedures. Finally, the 
presence of HLA antibodies in test sera makes identifying 
HNA antibodies difficult because granulocytes also express 
HLA class I antigens on their cell surface.
Preparation of Pure Granulocyte Suspensions
 The isolation of pure granulocyte suspensions from pe-
ripheral blood was greatly facilitated and simplified with 
Bøyum’s introduction in 1968 of the Ficoll-Isopaque gradi-
ent technique.80 Double-density gradient centrifugation is 
now the most widely used approach for the isolation and 
purification of granulocytes for serologic testing. The proce-
dure makes use of discontinuous Ficoll gradients, and nu-
merous publications exist describing the methodology and 
the recovery, purity, functional integrity, and activity of the 
isolated granulocytes.81–84
Granulocyte Antibody Detection and Antigen Typing 
 Laboratory approaches for the detection of granulocyte 
antibodies require procedures that are accurate, reproduc-
ible, and practical. Although numerous granulocyte sero-
logic assays have been described, not all meet these criteria. 
In addition to the assay used, the ability to detect antibodies 
in test specimens or antigens on test cells may also depend 
on target cell antigen density and the concentration and 
immunoglobulin type of the antibody in the test reagent. 
Therefore, the successful detection of granulocyte antibod-
ies often requires that a combination of methods be used.
 Although several methods for the detection of gran-
ulocyte-specific antibodies are used by the few laborato-
ries that perform this testing, the ISBT Working Party on 
Granulocyte Immunobiology, a worldwide consortium of 
16 laboratories that participate in the annual International 
Granulocyte Immunology Workshop (IGIW), have recom-
mended that granulocyte antibodies should be investigated 
using a minimum of two methods: the granulocyte immun-
ofluorescence test (GIFT) and the granulocyte agglutination 
test (GAT).85 Multiple workshops have shown the sensitiv-
ity of GIFT to far exceed that of GAT; however, agglutinat-
ing antibodies such as HNA-1c, HNA-3a, and HNA-4a are 
much more readily detectable in GAT and in many cases it 
is the only reliable method for detecting these specificities. 
For example, the seventh IGIW included a test specimen 
that contained an HNA-3a antibody that could only be de-
tected by GAT and the granulocyte chemiluminescence test 
(GCLT). Although GCLT has been useful in selective labora-
tory settings, it is not routinely used for clinical granulocyte 
antibody detection and is not discussed.
M.E. Clay et al.
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Antibody Detection Methods   
Granulocyte Agglutination Test  
 Lalezari86 developed the basis of this assay in the early 
1960s. Since that time, micro techniques and the use of 
pure granulocyte suspensions with optimized concentra-
tions of EDTA have vastly improved the performance of 
this test. Typically, a panel of three to five donors is selected 
to include all known neutrophil antigens currently defined 
by the ISBT consortium. Purified granulocytes are isolated 
from EDTA-anticoagulated peripheral whole blood using 
a double-density gradient. These granulocytes are then 
washed in PBS before use. The test is biphasic and is based 
on the intrinsic response of granulocytes to aggregate when 
stimulated by antibodies reacting to corresponding cell 
surface antigens. The resulting agglutination is the conse-
quence of the granulocyte activation that occurs during the 
sensitization phase, which induces the cells to form pseu-
dopods and slowly migrate toward one another during the 
aggregation phase, until membrane contact is established. 
Typically, the serum or plasma from the specimen being 
investigated is incubated with the granulocyte suspension 
for 4.5 to 6 hours at 30ºC.87 The reactions are evaluated us-
ing an inverted-phase microscope and graded from nega-
tive to 4+ on the basis of the percentage of cells that are 
agglutinated. Our laboratory has determined cutoff scores 
for both adult and pediatric patients (<6 years old) on the 
basis of the reaction grades established during microscopic 
evaluation. Both IgG and IgM antibodies are detected by 
this method.
Granulocyte Immunofluorescence Test
 Developed by Verheugt et al.88 in the late 1970s, this 
fluorescent “antiglobulin” technique is used for the detec-
tion of granulocyte alloantibodies and autoantibodies that 
are circulating and cell bound. As with the GAT, an anti-
body screening panel of three to five donors is selected 
to include all currently defined HNA antigens. A purified 
granulocyte suspension is prepared and treated with 1% 
paraformaldehyde for a short time to prevent nonspecific 
immunoglobulin binding to the neutrophil Fc receptors and 
to stabilize the cell membrane. Serum or plasma from the 
patient is then incubated with an optimized concentration 
of granulocytes for 30 minutes at 37ºC. After a wash step 
that removes unbound antibodies, the granulocytes are 
then incubated with F(ab′)2 fragments of a fluorescent con-
jugated anti-human antibody for approximately 30 min-
utes at room temperature in a dark environment. The as-
say’s performance is optimized with the use of a fluorescent 
secondary probe that can detect both IgM and IgG antibod-
ies (to ensure the detection of both primary and secondary 
immune responses) and the use of F(ab′)2 Ig fragments to 
prevent the probe from binding to the high concentrations 
of Fc receptors on granulocyte surface membranes. The cells 
undergo another wash cycle, are resuspended, and then are 
analyzed. Detection of the immunofluorescence reactions 
can be accomplished by using either a fluorescence-detect-
ing microscope or a flow cytometer. Evaluation by a flow 
cytometer has in most cases replaced the fluorescence mi-
croscope as more cells can be analyzed in a shorter time, 
resulting in improved assay sensitivity and reproducibility, 
and it does not require the expertise needed to evaluate the 
characteristic staining pattern seen with specific granulo-
cyte antibodies by microscopic analysis.
Monoclonal Antibody Immobilization of Granulocyte Antigens 
 The monoclonal antibody immobilization of granulo-
cyte antigens assay (MAIGA) is based on the platelet ver-
sion (MAIPA) developed by Kiefel et al. in 1987.89 MAIGA 
relies on the capture of neutrophil-specific antigen-antibody 
complexes by a murine monoclonal antibody onto a solid-
phase surface.90 The benefits of this test are twofold: first, 
this is currently the most sensitive assay for the detection of 
granulocyte antibodies, and second, the assay is designed to 
detect only HNA antibodies even when HLA antibodies are 
present in the test specimen. The disadvantage of this pro-
cedure is that it is very complex and requires highly skilled 
staff to perform the detailed techniques.
 Granulocytes are incubated with the test serum or plas-
ma for 30 minutes at 37ºC. This granulocyte suspension is 
then washed to remove any unbound immunoglobulins and 
incubated with a murine monoclonal antibody to a specific 
neutrophil glycoprotein for an additional 30 minutes. Af-
ter another wash step, the granulocyte membranes are dis-
rupted in a mild detergent and centrifuged. The resulting 
lysate is then transferred to polystyrene microwells coated 
with anti-mouse immunoglobulins for incubation. The 
trimolecular neutrophil antigen–patient HNA antibody–
murine monoclonal antibody complex present in the lysate 
is captured on the solid phase, whereas any HLA 
antibody-antigen complexes (if present) are removed by 
a subsequent wash step. Remaining complexes are then 
detected by the addition of anti-human IgG conjugated to 
horseradish peroxidase followed by a substrate (OPD dis-
solved in 30% H2O2), and the reaction is analyzed with a 
spectrophotometer.
 MAIGA can be used to detect antibodies specific 
to HNA-1a, HNA-1b, and HNA-1c antigens located on 
FcγRIIIb (CD16); HNA-2a present on gp 58- to 64-kDa 
(CD177); HNA-4a on the complement component receptor 
C3bi (CD11b); and HNA-5a on the LFA-1 receptor (CD11a). 
HNA-4a and HNA-5a antibodies can also be detected by a 
common CD18 monoclonal antibody.
Antigen Detection and Typing Methods   
 The same methodology that is used to detect antibodies 
in serum and plasma can be used to characterize the antigen 
phenotype of an individual’s granulocytes. Just as the short 
lifespan of granulocytes is a limitation to obtaining panel 
cells for antibody testing, it also restricts the ability to do 
antigen typing because granulocyte specimens must be tested 
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within 24 hours of collection to obtain reliable results. A 
sufficient volume of whole blood must be collected to obtain 
an adequate number of granulocytes for phenotyping. This 
can be a dilemma in pediatric patients or patients who are 
neutropenic. Because ample volume, freshness, and avail-
ability of granulocytes is critical, this also acts as a practical 
barrier to doing donor-recipient crossmatch testing during 
investigations of suspected granulocyte-antibody–mediat-
ed transfusion reactions such as TRALI. The highly charac-
terized antisera used to phenotype granulocytes should be 
free of HLA class I antibodies as their presence can result in 
a false-positive HNA typing. At a minimum, the titer of the 
HLA antibody should be weaker than the HNA antibody 
as it can then be readily diluted to a nonreactive level. An-
other constraint to phenotyping granulocytes is the limited 
availability of qualified antisera for the currently defined 
HNA antigens.
 Monoclonal antibodies specific to several HNA anti-
gens are commercially available and have been used to type 
granulocytes by GIFT using the flow cytometer. An advan-
tage to phenotyping by this method is that it can be done 
with whole blood instead of with isolated granulocytes.
 Because phenotyping granulocytes cannot often be per-
formed or can be unreliable if samples are not handled in a 
careful and timely manner, genotyping by PCR, which has 
less stringent sample age and handling restraints, can serve 
either as an alternative to or as confirmation of serologic 
results.
Granulocyte Genotyping   
 The discovery of the PCR in the 1980s facilitated the 
development of molecular methods that have now been ap-
plied to delineate the genetics and allelic variations of the 
HNAs. Initially, the characterization of the genes encoding 
the HNA-1 antigen system (HNA-1a, HNA-1b, and HNA-1c) 
allowed for the development of PCR assays using sequence-
specific primers (SSP) to differentiate the alleles. To com-
plicate matters there is a high degree of homology between 
the FCGR3A gene that encodes the FcγRIIIa granulocyte 
receptor and the FCGR3B gene where the three different 
HNA-1 polymorphisms reside. HNA-1a, HNA-1b, and HNA-
1c are encoded by FCGR3B*1, FCGR3B*2, and FCGR3B*3 
genes, respectively. FCGR3B*1 differs from FCGR3B*2 
by five nucleotide bases, and a single nucleotide polymor-
phism (SNP) differentiates FCGR3B*2 from 
FCGR3B*3 (Table 2). FCGR3A differs from 
FCGR3B at five different nucleotide locations 
(Table 2).
 Methods are also available to genotype 
the HNA-4a and HNA-5a alleles.71 Both of 
these polymorphisms are the result of SNPs. 
Even though the molecular sequence of HNA-
2a has been identified, genotyping methods 
to detect the gene that encodes this alloanti-
gen are not available. The HNA-2a negative 
phenotype is attributable to CD177 mRNA 
splicing defects, and no mutations have been detected in 
the CD177 introns or exons in these individuals.93 Because 
the gene encoding HNA-3a has only recently been identi-
fied, there has not been a genotyping procedure for this 
antigen, but the clinical importance of this antigen is sup-
porting efforts to get a molecular method developed.
 Genomic DNA (gDNA) can be isolated and purified 
from anticoagulated blood using any number of published 
methods. A unique set of sense and antisense oligonucle-
otide primers that border the DNA fragment to be amplified 
are added to a master mix of reagents that includes deoxy-
nucleoside triphosphates (dNTPs), Taq polymerase, a buf-
fer solution containing Mg2+, and the individual’s gDNA. 
The master mix is subjected to a series of 30 to 40 tempera-
ture changes that define the amplification cycles. Each cycle 
consists of three temperature steps that are critical in the 
amplification of the DNA target strands. The first step in 
the cycle typically involves heating the master mix to a tem-
perature of 95ºC. This denaturation step results in double-
stranded DNA separating into single strands by disrupting 
the hydrogen bonds between each nucleotide base pair. The 
annealing step follows in which the reaction temperature is 
lowered to 50ºC to 65ºC. This allows the primers to hybrid-
ize to the opposing strands of the target DNA. The final ex-
tension step heats the master mix from 71ºC to 72ºC, which 
results in DNA synthesis in the presence of Taq polymerase 
and dNTPs complementary to the oligonucleotide primers. 
A final extension step is added after all cycles have been 
completed to ensure that any remaining single-stranded 
DNA is fully elongated. The amplified double-stranded 
DNA (amplicon) is separated by size using agarose gel 
electrophoresis, stained with ethidium bromide, and visu-
alized by fluorescence using ultraviolet light. The sizes of 
the amplicons are determined by comparison with a DNA 
ladder, which contains DNA fragments of known sizes that 
were run alongside the PCR products during the agarose gel 
electrophoresis step.
Future Directions   
Solid-Phase Technology   
 The complement-dependent lymphocyte cytotoxicity 
assay was the first platform, developed nearly 50 years ago, 
for identifying HLA antibodies and remains the standard 
for the development of new methodologies in this field. 
M.E. Clay et al.
Table 2. Nucleotide differences for the three HNA-1 alleles (1a, 1b, and 1c) on 
FcγRIIIb and among the FcγRIII genes†
HNA Gene Polymorphic nucleotides
141 147 227 266 277 349 473 505 559 641 733
1a FCGR3B*1 G C A C G G A C G C T
1b FCGR3B*2 C T G C A A A C G C T
1c FCGR3B*3 C T G A A A A C G C T
FCGR3A G C G C G A G T T T C
†Information from references 91 and 92.
NOTE: Boldface indicates substituted nucleotides. 
FcγRIIIb = Fc gamma receptor IIIb; HNA = human neutrophil antigen.
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Multiple new technologies are now being used by HLA 
laboratories, and in the past few years solid-phase assays 
have been developed in which purified HLA molecules are 
bound to a well in a microtiter plate or to a bead. HLA an-
tibody is then detected either using an enzyme-linked im-
munosorbent assay (ELISA) technique or by analyzing the 
beads with a flow cytometer, which uses a new technology 
developed by Luminex (Austin, TX).94 A critical advantage 
of this technology is its ability to measure multiple analytes 
simultaneously in a single reaction system. The commer-
cially available test kits use purified HLA antigens bound 
to microbeads, which can be individually differentiated by 
varying ratios of internal fluorescent dye prepared during 
the manufacturing process. The test involves incubation of 
test sera with the panel of microbeads, and the bound HLA 
antibody is detected by a secondary R-phycoerythrin (PE) 
conjugated IgG (or IgM)–specific antibody.
 Analysis is done with the use of a Luminex flow analyz-
er in which the beads pass through two lasers, similarly to 
classic flow cytometry. One laser identifies the specific bead 
being analyzed, thereby identifying the unique HLA anti-
gen. The other laser detects the presence of bound Ig on the 
surface of the microbead. The color signals are then detect-
ed and processed into data for each reaction. A significant 
fluorescence shift from the negative control range indicates 
the presence of specific antibody in the test sample.
 The widespread use of Luminex technology by HLA 
laboratories has fostered commercial activity directed at 
using this technology for the detection of HNA antibodies 
that have been related to febrile and pulmonary transfusion 
reactions. One Lambda, Inc. (Canoga Park, CA), has devel-
oped recombinant cell lines for HNA-1a, -1b, -1c, -2a, and 
-4a, and these cell lines have allowed the production of pu-
rified proteins that have been individually immobilized on 
Luminex microbeads for use in their LABScreen Multiflow 
bead assay. Stroncek and colleagues95 evaluated the specific-
ity and sensitivity of this new procedure using 22 sera that 
had known HNA antibodies detected with the GA assay and 
140 samples from nontransfused men. All HNA antibody 
specificities (except 4a) recognized by GAT were detected 
in the solid-phase flow bead system (8 HNA-1a, 6 HNA-1b, 
1 HNA-1c, and 8 HNA-2a positive sera), and HNA-1c reac-
tivity was detected in four specimens that were negative by 
GAT. In addition, all of the 140 negative control samples 
had negative reactions when tested by LABSreen Multi, and 
the system was able to detect both HNA and HLA antibod-
ies (both class I and class II) in some individual specimens.95 
Although preliminary, these results suggest that this solid-
phase technology may emerge as a major achievement in 
the development of a new sensitive and specific platform 
for the detection of granulocyte antibodies in an automated 
manner with limited complexity and high cost efficiency.
Cell Lines Expressing HNA Antigens   
 Another approach to eliminate the need for freshly 
isolated granulocytes for granulocyte antibody screening 
has been the establishment of cell lines that express HNA 
antigens. In 1999 Bux’s group transfected Chinese ham-
ster ovary (CHO) cells with HNA-1a, HNA-1b, and HNA-
1c cDNA and established stable cell lines expressing these 
antigens.96 Although the cell lines were stable for 1 month 
at 4°C, they demonstrated high background fluorescence in 
the GIF assay and could only be used for the MAIGA, which 
limited their overall utility. More recently, Yasui et al.97,98 
transduced HNA genes into the human erythroleukemia 
cell line K562 and established a panel of K562 cell lines that 
stably expressed HNA-1a, -1b, -1c, -2a, -4a, -4b, -5a, and -5b 
for at least 1 year while being maintained in culture. They 
were not able to establish a cell line expressing HNA-3a be-
cause of the previous lack of biochemical and genetic infor-
mation for this antigen. The group’s report demonstrated 
the utility of using the cultured cells in the GIF assay to de-
tect HNA antibodies in serum samples from patients with 
HNA antibody–related disorders, but experience with this 
new cell line technology is very limited and it remains to be 
seen whether the cell lines can be maintained or preserved 
in a manner that would support the use of these cells for 
routine (nonresearch) granulocyte serology applications.
ISBT Working Party on Granulocyte Immunobiology 
 In 1989, Professor Alan Waters organized the UK Plate-
let and Granulocyte Serology Working Group, and 11 inter-
national laboratories participated in the First International 
Workshop on Granulocyte Serology. The objectives of this 
first workshop were as follows: (1) to initiate an exchange 
of sera among laboratories to evaluate the techniques be-
ing used for the detection of granulocyte antibodies, (2) to 
foster working relationships among laboratories involved 
in this field, and (3) to support the development of the sci-
ence and technology for the detection of granulocyte anti-
bodies.99
 The Working Party was initially affiliated with the Brit-
ish Blood Transfusion Society but is now affiliated with the 
ISBT. The goals of the Second Workshop, in 1996, were 
the (1) establishment of typed granulocyte panels by well-
defined typing sera, (2) proficiency testing of granulocyte 
antibody detection, (3) investigation of uncharacterized 
sera, (4) proficiency testing of HNA genotyping, and (5) ex-
change of information to establish standards in granulocyte 
serology.100 Fifteen international laboratories participated 
in the Fourth Workshop, in 2001, with the main objec-
tive being the establishment of a formal quality assurance 
(QA) scheme for granulocyte serology and molecular typing 
methods.85
 To date, the Working Party has conducted nine Granu-
locyte Serology Workshops and comprises 16 international 
member laboratories, which are listed in Table 3. Also, the 
American Red Cross Mid-America Blood Services Neutro-
phil & Platelet Immunology Laboratory has been a member 
of this consortium since its inception in 1989. The workshops 
continue to focus on the QA and standardization of the test 
systems, and the Working Party recently published its 
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serologic screening recommendations for the investigation 
and prevention of leukocyte antibody-mediated TRALI.101
Conclusions   
 Granulocyte antibody and antigen testing has played 
and continues to play a critical role for diagnosing and 
investigating relatively rare but potentially lethal clini-
cal conditions such as TRALI and immune neutropenias. 
Although mitigation strategies are already being imple-
mented nationwide, TRALI still appears to be a leading and 
preventable cause of transfusion fatalities. As advancing 
technology allows granulocyte antibody testing to be done 
on a less manual and larger scale with more standardized 
and reproducible results, it now has the potential to become 
even more valuable as a tool to increase blood safety by ac-
tually preventing transfusion reactions without compro-
mising an adequate supply of blood.
Acknowledgments   
 The authors would like to thank Penny Milne and Bob-
bie Gibson for their helpful assistance with the preparation 
of the manuscript.
References   
Lalezari P, Nussbaum M, Gelman, et al. Neonatal 1. 
neutropenia due to maternal isoimmunization. Blood 
1960;15:236–43.
Bux J, Jung KD, Kauth T, et al. Serological and clinical 2. 
aspects of granulocyte antibodies leading to alloimmune 
neonatal neutropenia. Transfus Med 1992;2:143–9.
Rodwell RL, Gray PH, Taylor KM, et al. Granulocyte 3. 
colony stimulating factor treatment for alloimmune 
neonatal neutropenia. Arch Dis Child Fetal Neonatal 
Ed 1996;75:F57–8.
Rodney GE, Lalezari P. HLA and neutrophil antigen 4. 
and antibody systems. In: Hoffman R, Benz E, Shattil 
SJ, eds. Hematology basic principles and practice. 3rd 
ed. New York: Churchill Livingstone, 2000:2220–41.
Lalezari P. Alloimmune neonatal neutropenia. In: En-5. 
gelfriet CP,Van Logham JJ, von dem Borne AEGKr, 
eds. Immunohaematology. Amsterdam: Elsevier Sci-
ence Publishers, 1984:179–86.
Clay M, Kline W, McCullough J. Serological examina-6. 
tion of postpartum sera for the presence of neutrophil-
specific antibodies (abstract). Transfusion 1981;21:616.
Levine DH, Madyastha P, Wade R, Levkoff AH. Neo-7. 
natal isoimmune neutropenia (abstract). Pediatr Res 
1981;15:296A.
Lalezari P, Bernard GE. An isologous antigen-antibody 8. 
reaction with human neutrophils, related to neonatal 
neutropenia. J Clin Invest 1966;45:1741–50.
Verheugt FWA, van Noord-Bokhorst JC, von dem 9. 
Borne AEGKr, et al. A family with alloimmune neonatal 
neutropenia: group specific pathogenicity of maternal 
antibodies. Vox Sang 1979;36:1–8.
van der Weerdt CM, Lalezari P. Another example of 10. 
isoimmune neonatal neutropenia due to anti-NA1. Vox 
Sang 1972;22:438–46.
Boxer LA, Yokoyama M, Lalezari P. Isoimmune neona-11. 
tal neutropenia. J Pediatr 1972;80:783–7.
Bux J, Ernst-Ludwig Stein, Bierling P, et al. Character-12. 
ization of a new alloantigen (SH) on the human neutro-
phil Fc gamma receptor IIIb. Blood 1997;89:1027–34.
Schuller RM, Stroncek DF, Alpan O, et al. Different re-13. 
sponses observed between G-CSF and GM-CSF therapy 
in a case of neonatal alloimmune neutropenia (ab-
stract). Transfusion 2008;48(Suppl):53A.
Bachowski GJ, Mair DC, Schuller RM, et al. Alloimmune 14. 
neonatal neutropenia in monozygous twins caused by 
antibody to FcγRIIIb in a mother lacking CD16 antigen 
(abstract). Transfusion 2007;47(Suppl):21A.
Stroncek DF, Sharpiro RS, Filipovich AH, et al. 15. 
Prolonged neutropenia resulting from antibodies to 
neutrophil-specific antigen NB1 following marrow 
transplantation. Transfusion 1993;33:158–63.
M.E. Clay et al.
Table 3. Members of the ISBT Working Party on Granulocyte 
Immunobiology
·  Platelet and Leucocyte Immunology Laboratory, EFS Ile de France, 
   Hopital Henri Mondor, Creteil, France
·  Leucocyte and Platelet Immunology Laboratory, Blood Service West of 
   the German Red Cross, Hagen, Germany 
·  The BloodCenter of Wisconsin, Platelet and Neutrophil Immunology 
   Laboratory, Milwaukee, WI, USA
·  Institute of Transfusion Medicine, University of Schleswig-Holstein, Kiel, 
   Germany
·  Australian Red Cross Blood Service-Queensland, Brisbane, Australia
·  Platelet and Granulocyte Immunology Laboratory, National Blood Se 
   vice, Bristol, UK
·  Blood Transfusion Center of Slovenia, Ljubljana, Slovenia
·  Centre de Transfusio I Banc de Teixitis, Hospital Vall d’Hebron, P. Vall 
   d’Hebron, Barcelona, Spain
·  Sanguin Diagnostics, Immunohaematology Diagnostic Department, 
   Amsterdam, The Netherlands
·  Institute for Clinical Immunology and Transfusion Medicine, Justus 
   Liebig University, Giessen, Germany
·  American Red Cross Mid-America Blood Services, Neutrophil & Platelet 
   Immunology Laboratory, St. Paul, MN, USA
·  Department of Transfusion Medicine, Graduate School of Medical Sc 
   ences, University of Tokyo, Tokyo, Japan
·  Department of Immunohaematology and Transfusion Medicine, Institute 
   of Haematology and Blood Transfusion, Warsaw, Poland
·  Aberdeen and North East Scotland Blood Centre, Scottish National 
   Blood Transfusion Service, Aberdeen, UK
·  Platelet and Leucocyte Immunology Laboratory, Institute of Biology, 
   Nantes, France
·  Department of Transfusion Medicine, Karolinska University Hospital, 
   Stockholm, Sweden
IMMUNOHEMATOLOGY, Volume 26, Number 1, 2010 19
Granuloycte serology: concepts and significance
de Haas M, Muniz-Diaz E, Alonso LG, et al. Neutrophil 16. 
antigen 5b is carried by a protein, migrating from 70 to 
95 kDa, and may be involved in neonatal alloimmune 
neutropenia. Transfusion 2000;40:222–7.
Fung L, Pitcher LA, Willett JE, et al. Alloimmune neo-17. 
natal neutropenia linked to anti-HNA-4a. Transfus 
Med 2003;13:49–52.
Bux J, Behrens G, Jaeger G, et al. Diagnosis and clinical 18. 
course of autoimmune neutropenia in infancy: analysis 
of 240 cases. Blood 1998;91:181–6.
Bux J, Kissel K, Nowak K, et al. Autoimmune neutrope-19. 
nia: clinical and laboratory studies in 143 patients. Ann 
Hematol 1991;63:249–52.
Stroncek D. Granulocyte antigens and antibody detec-20. 
tion. Vox Sang 2004;87(Suppl 1):91–4.
Sperner-Unterweger B, Czeipek I, Gaggl S, Geissler 21. 
D, Spiel G, Fleischhacker WW. Treatment of severe 
clozapine-induced neutropenia with granulocyte col-
ony stimulating factor (G-CSF). Remission despite 
continuous treatment with clozapine. Br J Psychiatry 
1998;172:82–4.
Stroncek DF. Drug-induced immune neutropenia. 22. 
Transfus Med Rev 1993;7:268–74.
Mamus SW, Burton JD, Groat JD, et al. Ibuprofen-23. 
associated pure white cell aplasia. N Engl J Med 
1986;314:624–5.
Holness L, Knippen MA, Simmons L, et al. Fatalities 24. 
caused by TRALI. Transfus Med Rev 2004;18:184–8.
Brittingham TE. Immunologic studies on leukocytes. 25. 
Vox Sang 1952;2:242–8.
Barnard, RD. Indiscriminate transfusion: a critique of 26. 
case reports illustrating hypersensitivity reactions. N Y 
State J Med 1951;51:2399–402.
Popovsky MA, Moore SB. Diagnostic and pathogenic 27. 
considerations in transfusion-related acute lung injury. 
Transfusion 1985;25:573–7.
Bux J, Sachs UJ. The pathogenesis of transfusion-28. 
related acute lung injury (TRALI). Br J Haematol 
2007;136:788–99.
Reil A, Keller-Stanislawski B, Gunay S, et al. Specifici-29. 
ties of leukocyte alloantibodies in transfusion-related 
acute lung injury and results of leukocyte antibody 
screening of blood donors. Vox Sang 2008;95:313–17.
Ward HN. Pulmonary infiltrates associated with leu-30. 
koagglutinin transfusion reactions. Ann Intern Med 
1970;73:689–94.
Thompson JS, Severson CD, Parmely MJ, et al. Pul-31. 
monary ‘hypersensitivity’ reactions induced by trans-
fusion of non-HLA lekoagglutinins. N Engl J Med 
1971;284:1120–5.
Nordhagen R, Conradi M, Drotorp SM. Pulmonary re-32. 
action associated with transfusion of plasma containing 
anti-5b. Vox Sang 1986;51:102–7.
Kopko PM, Marshall CS, MacKenzie MR, et al. Transfu-33. 
sion-related acute lung injury. Report of a clinical look-
back investigation. JAMA 2002;287:1968–71.
Davoren A, Curtis BR, Shulman IA, et al. TRALI due to 34. 
granulocyte-agglutinating human neutrophil antigen-
3a (5b) alloantibodies in donor plasma: a report of 2 
fatalities. Transfusion 2003;43:641–5.
Silliman CC, Curtis BR, Kopko PM, et al. Donor anti-35. 
bodies to HNA-3a implicated in TRALI reactions prime 
neutrophils and cause PMN-mediated damage to hu-
man pulmonary microvascular endothelial cells in a 
two-event in vitro model. Blood 2007;109:1752–5.
Sachs UJ, Chavakis T, Fung L, et al. Human alloanti-36. 
body anti-MART interferes with Mac-1-dependent leu-
kocyte adhesion. Blood 2004;104:727–34.
Kopko PM, Curtis BR, Kelher M, et al. Merging the 37. 
pathogenesis of transfusion-related acute lung injury: 
the priming activity of the 5b (HNA-3) antibody (ab-
stract). Transfusion 2004;44(Suppl 1):22A.
Sachs UJ, Hattar K, Weissman N, et al. Antibody-38. 
induced neutrophil activation as a trigger for trans-
fusion-related acute lung injury in an ex vivo rat lung 
model. Blood 2006;107:1217–9.
Fung YL, Silliman CS. The role of neutrophils in the 39. 
pathogenesis of transfusion-related acute lung injury. 
Transfusion Med Rev 2009;23:266–83.
Lalezari P, Radel E. Neutrophil-specific antigens: im-40. 
munology and clinical significance. Semin Hematol 
1974;11:281–90.
Lalezari P, Murphy GB, Allen FH. NB1, a new neutro-41. 
phil antigen involved in the pathogenesis of neonatal 
neutropenia. J Clin Invest 1971;50:1108–15.
Huang ST, Lin J, McGowan El, et al. NB2, a new allele 42. 
of NB1 antigen involved in febrile transfusion reaction 
(abstract). Transfusion 1982;22:426.
Lalezari P, Petrosova M, Jiang AF. NB2, an allele of 43. 
NB1 neutrophil specific antigen: relationship to 9a (ab-
stract). Transfusion 1982;22:433.
Lalezari P, Thelenfeld B, Weinstein WJ. The third neu-44. 
trophil antigen. In: Terasaki PI, ed. Histocompatibility 
testing. Baltimore: Williams & Wilkins, 1970:319–22.
Verheugt FWA, von dem Borne AEGKr, van Noord-45. 
Bokhorst JC, et al. ND1, a new neutrophil granulocyte 
antigen. Vox Sang 1978;35:13–17.
Claas FHJ, Langerak J, Sabbe LJM, et al. NE1, a 46. 
new neutrophil specific antigen. Tissue Antigens 
1979;13:129–34.
Thompson JS, Overlin VL, Herbick JM, et al. New 47. 
granulocyte antigens demonstrated by microgranulo-
cytotoxicity assay. J Clin Invest 1980;65:1431–9.
Hasegawa T, Bergh OJ, Mickay MR, et al. Prelimi-48. 
nary human granulocyte specificities. Transplant Pro 
1975;7(Suppl 1):75–80.
IMMUNOHEMATOLOGY, Volume 26, Number 1, 201020
Caplan SN, Berkman EM, Babior BM. Cytotoxins 49. 
against a granulocyte antigen system: detection by a 
new method employing cytochalasin-B-treated cells. 
Vox Sang 1977;33:206–11.
Van Leeuwen A, Eerrise JG, van Room JJ. A new leu-50. 
kocyte group with two alleles: leukocyte group five. Vox 
Sang 1964;9:431–7.
Van Rood JJ, van Leeuwen A, Schippers AMJ, et al. 51. 
Immunogenetics of the group four, five and nine sys-
tems. In: Curton ES, Mattiuz PI, Tosi RM, eds. Histo-
compatibility testing. Baltimore: Williams & Wilkins, 
1967:203–19.
Kline WE, Press C, Clay M, et al. Three sera defining a 52. 
new granulocyte-monocyte–T lymphocyte antigen. Vox 
Sang 1986;50:181–6.
Madyastha PR, Glassman A, Levine D, et al. Identifi-53. 
cation of a new neutrophil antigen (CN1) more preva-
lent among American blacks (abstract). Transfusion 
1983;23:426.
Schnell M, Halligan G, Herman J. A new granulocyte 54. 
antibody directed at a high frequency antigen causing 
neonatal alloimmune neutropenia (abstract). Transfu-
sion 1989;29(Suppl):46S.
Rodwell RL, Tudehope DI, O’Regan P, et al. Alloimmune 55. 
neonatal neutropenia in Australian aboriginals: an un-
recognized disorder? Transfusion Med 1991;1:63–7.
Stroncek DF, Ramsey G, Herr GP, et al. Identification of 56. 
a new white cell antigen. Transfusion 1994;34:706–11.
Bux J, Bierling P, von dem Borne AE, et al. ISBT Granu-57. 
locyte Antigen Working Party. Nomenclature of granu-
locyte alloantigens. (letter).Vox Sang 1999;77:251.
Bux J. Human neutrophil alloantigens. Vox Sang 58. 
2008;94:277–85.
Greinacher A, Wesche J, Hammer E, et al. Character-59. 
ization of the human neutrophil alloantigen-3a. Nature 
Med 2010;16:45–8.
Curtis BR, Cox NJ, Sullivan MJ, et al. The neutrophil 60. 
alloantigen HNA-3a (5b) is located on choline trans-
porter-like protein 2 (CTL2) and appears to be en-
coded by an R>Q 154 amino acid substitution. Blood 
2010;115:2073-6.  
Shows TB, McAlpine PJ, Boucheix C, et al. Guidelines 61. 
for human gene nomenclature. An international system 
for human gene nomenclature (ISGN, 1987). Cytogenet 
Cell Genet 1987;46:11–28.
Stroncek DF, Skubitz KM, Plachta LB, et al. Alloim-62. 
mune neonatal neutropenia due to an antibody to the 
neutrophil Fc-gamma receptor III with maternal defi-
ciency of CD16 antigen. Blood 1991;77:1572–80.
Stroncek DF, Skubitz K, McCullough JJ. Biochemical 63. 
nature of the neutrophil-specific antigen NB1. Blood 
1990;75:744–55.
Matsuo K, Lin A, Procter JL, et al. Variations in the 64. 
expression of granulocyte antigen NB1. Transfusion 
2000;40:654–62.
Bux J, Jung KD, Kauth T, et al. Serological and clinical 65. 
aspects of granulocyte antibodies leading to alloimmune 
neonatal neutropenia. Transfusion Med 1992;2:143–9.
Bux J. Granulocyte antibody mediated neutropenias 66. 
and transfusion reactions. Infusions Ther Transfusion 
Med 1999;26:152–7.
Bux J, Becker F, Seeger W, et al. Transfusion-related 67. 
acute lung injury due to HLR-A2-specific antibodies in 
recipient and NB1-specific antibodies in donor blood. 
Br J Haematol 1996;93:707–13.
Stroncek DF, Shankar RH, Herr GP. Quinine-68. 
dependent antibodies to neutrophils react with a 60 
kD glycoprotein on which neutrophil-specific antigen 
NB1 is located and an 85 kD glycosylphosphatidylinos-
itol–linked N-glycosylated plasma membrane protein. 
Blood 1993;81:2758–66.
Lalezari P, Bernard GE. Identification of a specific 69. 
leukocyte antigen: another presumed example of 5b. 
Transfusion 1965;5:132–42.
de Haas M, Muniz-Diaz E, Alonso LG, et al. Neutrophil 70. 
5b is carried by a protein, migrating from 70 to 95 kDa, 
and may be involved in neonatal alloimmune neutrope-
nia. Transfusion 2000;40:222–7.
Simsek S, van der Schoot CE, Daams M, et al. Molecu-71. 
lar characterization of antigenic polymorphisms (ONDa 
and MARTa) of the ß2 family recognized by human leu-
kocyte alloantisera. Blood 1996;88:1350–8.
Fung L, Pitcher LA, Willett JE, et al. Alloimmune neo-72. 
natal neutropenia linked to anti-HNA-4a. Transfusion 
Med 2003;13:49–52.
Hartman KR, Wright DG. Identification of autoantibod-73. 
ies specific for the neutrophil adhesion glycoproteins 
CD11b/CD18 in patients with autoimmune neutro-
penia. Blood 1991;78:1096–104.
Kelton JG, Bebenek G. Granulocytes do not have sur-74. 
face ABO antigens. Transfusion 1985;25:567–9.
Dunstan RA, Simpson MB, Sanfilippo FP. Absence of 75. 
specific HLA-DR antigens on human platelets and neu-
trophils (abstract). Blood 1984;64:85a.
Thorsby E. HLA antigens on human granulocytes stud-76. 
ied with cytotoxic iso-antisera obtained by skin graft-
ing. Scan J Haematol 1969;6:119–27.
Sachs UJ,  Bux  J. TRALI after transfusion of cross-match-77. 
positive granulocytes. Transfusion 2003;43:1683–6.
Stroncek DF, Leonard K, Eiber G, et al. Alloimmuni-78. 
zation after granulocyte transfusions. Transfusion 
1996;36:1009–15.
McCullough J, Clay M, Hurd D, et al. Effect of leuko-79. 
cyte antibodies and HLA matching on the intravascular 
recovery, survival, and tissue localization of 111-indium 
granulocytes. Blood 1986;67:522–8.
M.E. Clay et al.
IMMUNOHEMATOLOGY, Volume 26, Number 1, 2010 21
Granuloycte serology: concepts and significance
Bøyum A. Isolation of mononuclear cells and granu-80. 
locytes from blood. Isolation of mononuclear cells by 
one centrifugation and of granulocytes by combining 
centrifugation and sedimentation at 1g. Scan J Clin Lab 
Invest 1968;21(Suppl 97):77–89.
English D, Anderson BR. Single-strep separation of red 81. 
blood cells, granulocytes, and mononuclear leukocytes 
on discontinuous density gradients of Ficoll-Hypaque. 
J Immunol Methods 1975;5:249–52.
Ferrante A, Thong YH. A rapid one-step procedure for 82. 
purification of mononuclear and polymorphonuclear 
leukocytes from human blood using a modification of 
the Hypaque-Ficoll technique. J Immunol Methods 
1978;24:389–93.
Ferrante A, Thong HY. Optimal conditions for simultaneous 83. 
purification of mononuclear and polymorphonuclear 
leukocytes from human blood by the Hypaque-Ficoll 
method. J Immunol Methods 1980;36:109–17.
Madyastha P, Madyastha KR, Wade T, et al. An im-84. 
proved method for rapid layering of Ficoll-Hypaque 
double density gradients suitable for granulocyte sepa-
ration. J Immunol Methods 1982;42:281–6.
Lucas G, Rogers S, de Haas M, et al. Report on the 85. 
Fourth International Granulocyte Immunology Work-
shop: progress toward quality assessment. Transfusion 
2002;42:462–8.
Lalezari P, Pryce S. Detection of neutrophil and plate-86. 
let antibodies in immunologically induced neutrope-
nia and thrombocytopenia. In: Rose NR, Friedman H, 
eds. Manual of clinical immunology. Washington, DC: 
American Society of Microbiology 1980;744–9.
McCullough J, Clay ME, Press C, et al. Granulocyte se-87. 
rology: a clinical and laboratory guide. Chicago: ASCP 
Press, 1988:12–14, 168–71.
Verheugt FWA, Von dern Borne AEGKr, Decary S, et 88. 
al. The detection of granulocyte alloantibodies with 
an indirect immunofluorescence test. Br J Haematol 
1977;36:533–44.
Kiefel V, Santoso S, Weisheit M, et al. Monoclonal anti-89. 
body-specific immobilization of platelet antigens (MAI-
PA): a new tool for the identification of platelet reactive 
antibodies. Blood 1987;70:1722–6.
Minchinton R, Noonan K, Johnson TJ. Examining 90. 
technical aspects of the monoclonal antibody im-
mobilization of granulocyte antigen assay. Vox Sang 
1997;73:87–92.
Stroncek D. Neutrophil alloantigens. Transfusion Med 91. 
Rev 2002;16:67–75.
Wang E, Marincola FM, Stroncek D. Human leukocyte 92. 
antigens and human neutrophil antigens systems. In: 
Hoffman R, Benz E, Shattil Sj, et al., eds. Hematology: 
basic principel and practices 4th ed. Philadelphia: El-
sevier, 2005:2401–22.
Kissel K, Scheffler S, Kerowgan M, et al. Molecu-93. 
lar basis of NB1 (HNA-2a, CD177) deficiency. Blood 
2002;99:4231–3.
Vigrali DA. Multiplexed particle-based flow cytometric 94. 
assays. J Immunol Methods 2000;243:243–55.
Stroncek DF, Adams S, Lee JH, et al. Neutrophil anti-95. 
body testing. ASHI Q 2008;32:68–72.
Bux J, Kissel K, Hofmann C, et al. The use of allele-spe-96. 
cific recombinant Fcγ receptor IIIb antigens for the de-
tection of granulocyte antibodies. Blood 1999;93:357–
62.
Yasui K, Miyazaki T, Matsuyama N, et al. Establish-97. 
ment of cell lines stably expressing HNA-1a, 1b, and 
-2a antigen with low background reactivity in flow cy-
tometric analysis. Transfusion 2007;47:478–86.
Yasui K, Hirayama F, Matsuyama N, et al. New cell lines 98. 
express HNA-1c, -4a, -4b, -5a, or -5b for identification 
of HNA antibodies. Transfusion 2008;48:1037–9.
Lucas GF, Carrington PA. Results of the First Inter-99. 
national Granulocyte Serology Workshop. Vox Sang 
1990;59:251–6.
Bux J, Chapman J. Report on the Second Interna-
tional Granulocyte Serology Workshop. Transfusion 
1997;37:977–83.
ISBT Working Party on Granulocyte Immunobiol-
ogy. Recommendations of the ISBT Working Party on 
Granulocyte Immunobiology for leukocyte antibody 
screening in the investigation and prevention of 
antibody-mediated transfusion-related acute lung in-
jury. Vox Sang 2009;96:266–7.
Mary E. Clay, MS, MT(ASCP), (corresponding author) Di-
rector, Transfusion Medicine, Research and Development 
Program, University of Minnesota Medical School, De-
partment of Laboratory Medicine and Pathology, MMC 
198, D-251 Mayo Building, 420 Delaware Street, SE, Min-
neapolis, MN 55455, and Consultant, Neutrophil & Plate-
let Immunology Laboratory, American Red Cross, Mid-
America Blood Services Region, 100 South Roberts Street, 
St. Paul, MN 55107, Randy M. Schuller, BS, MT(ASCP), 
Supervisor, and Gary J. Bachowski, MD, PhD, Assistant 
Medical Director, Neutrophil and Immunobiology Labo-
ratory, American Red Cross, Mid-America Blood Services 




For information concerning the National 
Reference Laboratory for Blood Group 
Serology, including the American Rare 
Donor Program, please contact Sandra 
Nance, by phone at (215) 451-4362, by fax at 
(215) 451-2538, or by e-mail at snance@usa.
redcross.org
